The role of FVIII/Anti-FVIII antibody Immune Complexes in Preventing FVIII-Specific Antibody Production in a Hemophilia A Mouse Model [PDF]
Abstract Background: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of FVIII. Patients can develop anti-FVIII IgG, rendering FVIII therapy ineffective. Antibody production can be suppressed by targeting CD32b receptors in B cells using ICs.
Dadashi Zadeh, Ghazaleh
core +3 more sources
Journal of Thrombosis and Haemostasis, 2020 Prophylactic replacement therapy in hemophilia A (HA) patients does not adequately prevent bleeds and arthropathic complications. A more refined understanding of the relationship between coagulation factor VIII (FVIII) levels and bleeding risk during protein prophylaxis, or with gene therapy, is needed to improve patient care.Investigate this ...
Karin M, Lövgren +8 more
openaire +3 more sources
An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia. [PDF]
Liver IntABSTRACT Background & Aims Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations.
Bitto N +14 more
europepmc +2 more sources
EFFECT OF FVIII CO-ADMINISTRATED WITH IVIG IN IMMUNITY TO FVIII IN HEMOPHILIA A MICE [PDF]
, 2016 Master of Applied Science (MASc)
Afraz, Sajjad
core +3 more sources
Platelets compensate for poor thrombin generation in type 3 von Willebrand disease
Platelets, 2020 In type 3 von Willebrand disease (VWD3), the most severe form with absent von Willebrand factor (VWF), the bleeding phenotype is variable. Platelet contribution to the hemostatic defect in VWD3 calls upon further studies. We investigated the contribution
Timea Szanto +4 more
doaj +1 more source
Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
Frontiers in Immunology, 2020 Anti-factor VIII (fVIII) alloantibodies, which can develop in patients with hemophilia A, limit the therapeutic options and increase morbidity and mortality of these patients.
Patricia E. Zerra +15 more
doaj +1 more source
Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
Molecular Therapy: Methods & Clinical Development, 2020 The delivery of factor VIII (FVIII) through gene and/or cellular platforms has emerged as a promising hemophilia A treatment. Herein, we investigated the suitability of human placental cells (PLCs) as delivery vehicles for FVIII and determined an optimal
Nadia El-Akabawy +14 more
doaj +1 more source
Journal of Blood Medicine, 2023 Gili Kenet,1,2 Thomas Moulton,3 Brian M Wicklund,4 Sanjay P Ahuja,5 Miguel Escobar,6 Johnny Mahlangu7 1National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel; 2The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv,
Kenet G +5 more
doaj
FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting [PDF]
Blood, 1987 We used immunoblotting of purified factor VIII coagulant protein (FVIII) to localize FVIII inhibitor epitopes in 76 inhibitor plasmas to either the 92-kd FVIII polypeptide (and its 54-kd and/or 44-kd thrombin fragments), the 80-kd polypeptide (and its 72-kd thrombin fragment), or both of these polypeptides.
C A, Fulcher +2 more
openaire +3 more sources
Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII. [PDF]
PLoS ONE, 2013 The formation of inhibitory antibodies directed against coagulation factor VIII (FVIII) is a severe complication in the treatment of hemophilia A patients. The induction of anti-FVIII antibodies is a CD4(+) T cell-dependent process.
Simon D van Haren +7 more
doaj +1 more source